CN113194936A - 含新型化合物和钙调磷酸酶抑制剂的用于预防和治疗移植排斥反应或移植排斥疾病的组合物 - Google Patents
含新型化合物和钙调磷酸酶抑制剂的用于预防和治疗移植排斥反应或移植排斥疾病的组合物 Download PDFInfo
- Publication number
- CN113194936A CN113194936A CN201980073598.8A CN201980073598A CN113194936A CN 113194936 A CN113194936 A CN 113194936A CN 201980073598 A CN201980073598 A CN 201980073598A CN 113194936 A CN113194936 A CN 113194936A
- Authority
- CN
- China
- Prior art keywords
- cells
- rejection
- transplantation
- transplant rejection
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180136107A KR102147802B1 (ko) | 2018-11-07 | 2018-11-07 | 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물 |
| KR10-2018-0136107 | 2018-11-07 | ||
| PCT/KR2019/015055 WO2020096371A1 (ko) | 2018-11-07 | 2019-11-07 | 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113194936A true CN113194936A (zh) | 2021-07-30 |
Family
ID=70612506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980073598.8A Pending CN113194936A (zh) | 2018-11-07 | 2019-11-07 | 含新型化合物和钙调磷酸酶抑制剂的用于预防和治疗移植排斥反应或移植排斥疾病的组合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11969397B2 (https=) |
| EP (1) | EP3878443A4 (https=) |
| JP (1) | JP7470683B2 (https=) |
| KR (1) | KR102147802B1 (https=) |
| CN (1) | CN113194936A (https=) |
| AU (1) | AU2019377749B2 (https=) |
| CA (1) | CA3118881A1 (https=) |
| WO (1) | WO2020096371A1 (https=) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112351784A (zh) * | 2019-05-17 | 2021-02-09 | 托莱罗根尼有限责任公司 | 用于移植中的特异性免疫抑制的mic治疗 |
| CN115843745A (zh) * | 2021-09-26 | 2023-03-28 | 泰州迈博太科药业有限公司 | 一种人源化肠炎小鼠模型的构建方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015167243A1 (ko) * | 2014-04-29 | 2015-11-05 | 가톨릭대학교 산학협력단 | 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도 |
| KR20160074415A (ko) * | 2014-12-18 | 2016-06-28 | 가톨릭대학교 산학협력단 | 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물 |
| CN106458869A (zh) * | 2014-04-29 | 2017-02-22 | 韩国加图立大学校产学协力团 | 具有免疫疾病治疗效果的新型化合物及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8637038B2 (en) | 2011-04-12 | 2014-01-28 | Rigel Pharmaceuticals, Inc. | Methods for inhibiting allograft rejection |
| US10369121B2 (en) | 2013-08-23 | 2019-08-06 | The Catholic University Of Korea Industry-Academic Cooperation Foundation | Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing biguanide derivative compound as active ingredient |
| KR101613371B1 (ko) | 2014-11-10 | 2016-04-18 | 가톨릭대학교 산학협력단 | 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도 |
| KR20180038355A (ko) | 2016-10-06 | 2018-04-16 | 서울과학기술대학교 산학협력단 | 탄성 및 기계적 물성이 우수한 탄성 고분자-세라믹 하이브리드 필름 및 이의 제조방법 |
| KR20190045513A (ko) | 2017-10-24 | 2019-05-03 | 가톨릭대학교 산학협력단 | Sd282 화합물 또는 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 후 면역 질환의 예방 및 치료용 조성물 |
-
2018
- 2018-11-07 KR KR1020180136107A patent/KR102147802B1/ko active Active
-
2019
- 2019-11-07 AU AU2019377749A patent/AU2019377749B2/en active Active
- 2019-11-07 CN CN201980073598.8A patent/CN113194936A/zh active Pending
- 2019-11-07 US US17/290,637 patent/US11969397B2/en active Active
- 2019-11-07 JP JP2021524277A patent/JP7470683B2/ja active Active
- 2019-11-07 EP EP19882758.6A patent/EP3878443A4/en active Pending
- 2019-11-07 WO PCT/KR2019/015055 patent/WO2020096371A1/ko not_active Ceased
- 2019-11-07 CA CA3118881A patent/CA3118881A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015167243A1 (ko) * | 2014-04-29 | 2015-11-05 | 가톨릭대학교 산학협력단 | 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도 |
| CN106458869A (zh) * | 2014-04-29 | 2017-02-22 | 韩国加图立大学校产学协力团 | 具有免疫疾病治疗效果的新型化合物及其应用 |
| KR20160074415A (ko) * | 2014-12-18 | 2016-06-28 | 가톨릭대학교 산학협력단 | 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물 |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112351784A (zh) * | 2019-05-17 | 2021-02-09 | 托莱罗根尼有限责任公司 | 用于移植中的特异性免疫抑制的mic治疗 |
| CN115843745A (zh) * | 2021-09-26 | 2023-03-28 | 泰州迈博太科药业有限公司 | 一种人源化肠炎小鼠模型的构建方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220031637A1 (en) | 2022-02-03 |
| EP3878443A4 (en) | 2022-08-24 |
| WO2020096371A1 (ko) | 2020-05-14 |
| US11969397B2 (en) | 2024-04-30 |
| JP7470683B2 (ja) | 2024-04-18 |
| EP3878443A1 (en) | 2021-09-15 |
| AU2019377749B2 (en) | 2024-10-03 |
| AU2019377749A2 (en) | 2021-06-03 |
| CA3118881A1 (en) | 2020-05-14 |
| KR102147802B1 (ko) | 2020-08-25 |
| KR20200052743A (ko) | 2020-05-15 |
| JP2022513590A (ja) | 2022-02-09 |
| AU2019377749A1 (en) | 2021-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4628792B2 (ja) | 免疫疾患治療用ラパマイシン及びil−10 | |
| KR102033276B1 (ko) | T 조절 세포의 생체 내 확장 방법 | |
| EP2289552A1 (en) | An immunosuppressive agent plus anti-TCR antibodies for the induction of chimerism in transplantation | |
| KR20060050555A (ko) | 면역질환의 치료용 디페노일 구조 화합물 | |
| CN113194936A (zh) | 含新型化合物和钙调磷酸酶抑制剂的用于预防和治疗移植排斥反应或移植排斥疾病的组合物 | |
| KR20190045513A (ko) | Sd282 화합물 또는 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 후 면역 질환의 예방 및 치료용 조성물 | |
| CN120283040A (zh) | 用于1型糖尿病治疗的具有免疫调节剂、dyrk1a抑制剂和glp1r激动剂的组合疗法 | |
| KR102014349B1 (ko) | Jak 억제제를 포함하는 면역반응 억제용 조성물 | |
| JP5815767B2 (ja) | 免疫学的疾患の処置のためのチモシンα1の使用 | |
| CN116744913A (zh) | 包含苯衍生物作为免疫抑制剂的免疫抑制药物组合物 | |
| US20070207129A1 (en) | Compositions and methods for inducing chimerism in a subject | |
| JPH11510806A (ja) | 免疫抑制治療のためのインターロイキン10およびシクロスポリンの併用 | |
| US20250009817A1 (en) | Immunomodulating composition containing gasseri | |
| WO2005055920A2 (en) | Compositions and methods for treatment of psychiatric disorders | |
| KR20120026208A (ko) | Sta-21을 유효성분으로 함유하는 암 또는 면역질환의 예방 및 치료용 조성물 | |
| CN103896812A (zh) | N,n’-二环己基-n-高级脂肪酸酰脲类似物及其制药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210730 |
|
| RJ01 | Rejection of invention patent application after publication |